Białek Sławomir, Górko Dariusz, Zajkowska Agnieszka, Kołtowski Łukasz, Grabowski Marcin, Stachurska Anna, Kochman Janusz, Sygitowicz Grażyna, Małecki Maciej, Opolski Grzegorz, Sitkiewicz Dariusz
Kardiol Pol. 2015;73(8):613-9.
The biochemical confirmation of myocardial infarction is based on cardiac troponin (cTnI or cTnT) determination. Recent scientific results suggested that microRNAs (miRNAs) might become a new biomarker of tissue injury.
To evaluate the release kinetics of circulating heart-specific miRNA-208a and also to test the hypothesis that miRNA-208a can serve as an accessible, diagnostically sensitive plasma biomarker of ST-elevation acute myocardial infarction (STEMI).
Nineteen STEMI patients (four women and 15 men, aged 44-85 years), 12 patients with stable coronary artery disease (CAD), and eight patients with a negative observation of CAD as a control group were studied. Blood samples were collected on admission and at three, six, 12, 24, and 48 h afterwards; in the CAD and control group blood samples were taken only once. Plasma levels of miRNA-208a determined by real-time polymerase chain reaction and their relative fold changes were calculated. cTnI and creatinine kinase (CK)-MB mass were also measured in the patients’ serum samples.
miRNA-208a was increased in STEMI patients at the time of admission and nearly undetectable in CAD patients and controls. The peak of miRNA-208a was observed at 3 h after reperfusion (p < 0.001). The traditional biomarkers (cTnI and CK-MBmass), which increase later in comparison to miRNA-208a reaching the maximum concentrations 6 h after reperfusion, were observed. Circulating miRNA-208a levels strongly correlated with cTnI and CK-MBmass released from the infarcted area.
These results demonstrate that plasma miRNA-208a is an interesting and promising candidate for a new biomarker released early after onset of myocardial infarction.
心肌梗死的生化确诊基于心肌肌钙蛋白（cTnI或cTnT）测定。近期科学研究结果表明，微小RNA（miRNA）可能成为组织损伤的新型生物标志物。
评估循环中心脏特异性miRNA-208a的释放动力学，并验证miRNA-208a可作为ST段抬高型急性心肌梗死（STEMI）一种易于获取、诊断敏感的血浆生物标志物这一假说。
研究对象包括19例STEMI患者（4例女性，15例男性，年龄44 - 85岁）、12例稳定型冠状动脉疾病（CAD）患者以及8例CAD检查结果为阴性的患者作为对照组。入院时及之后3、6、12、24和48小时采集血样；CAD组和对照组仅采集一次血样。采用实时聚合酶链反应测定血浆miRNA-208a水平并计算其相对倍数变化。同时测定患者血清样本中的cTnI和肌酸激酶（CK）-MB质量浓度。
STEMI患者入院时miRNA-208a升高，而CAD患者及对照组中几乎检测不到。miRNA-208a在再灌注后3小时达到峰值（p < 0.001）。观察到传统生物标志物（cTnI和CK-MB质量浓度）在再灌注6小时后达到最高浓度，相比miRNA-208a升高时间较晚。循环miRNA-208a水平与梗死区域释放的cTnI和CK-MB质量浓度密切相关。
这些结果表明，血浆miRNA-208a是心肌梗死发病后早期释放的新型生物标志物的一个有趣且有前景的候选指标。
